You recently switched from Novartis to Unipharm. Given the major differences in environment and portfolio, what was it about Unipharm in particular that attracted you and…
In Conversation
Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and…
Following Takeda’s acquisition of Nycomed earlier this year, how has the transaction affected your operations in Ukraine and what synergies were generated by it? Regarding the…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr.…
“ Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? ”
Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague…
Let us begin by introducing BACHI, its area of focus and scope of activities? BACHI is a fairly young independent association of the consumer healthcare industry,…
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global…
“ Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and evolution of the corporate vision… ”
To start off, we see that you have been with Cegedim Romania for 10 years, after running your own business initially. What would you say have…
Within a broad assessment of Romania’s investment climate, there is no doubt that every country has some key factors upon which can be capitalized to attract…
You have become the head of Novo Nordisk’s operations in Romania in March 2008. Can you first give our readers an idea on how the market…
